JUBLPHARMA.NS Stock Analysis
JU
Avoid
Based on Eyestock quantitative analysis, JUBLPHARMA.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Jubilant Pharmova Ltd. engages in the provision of basic organic chemicals. The company is headquartered in Noida, Uttar Pradesh and currently employs 1,034 full-time employees. The firm's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.